NCT02648932终止2 期
The Rapid Study: Randomized (RA) Phase (P) II Study To Expedite Allogeneic Transplant With Immediate (I) Haploidentical Plus Unrelated Cord Donor (D) Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- Time to Transplant
研究概览
简要总结
The study seeks to compare time from formal search to hematopoietic cell transplantation (HCT) for patients 18 years and older, randomized between haplo-cord search and matched unrelated donor (MUD) search for patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
详细描述
Primary Objectives
To compare time from formal search to hematopoietic cell transplantation (HCT) for patients 18 years and older, randomized between haplo-cord search and matched unrelated donor (MUD) search for patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
Secondary Objectives
- To compare the percentage of patients who undergo HCT in each study cohort
- To evaluate overall survival from time to randomization by study cohort
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •for Search Phase:
- •Diagnosis of acute myeloid leukemia (AML) or high or very high-risk MDS by international prognostic scoring system revised for whom transplant is recommended
- •18 years of age or older
- •Subject is likely to be considered for allogeneic transplant in the opinion of the transplant physician (based on age of patient, health, cytogenetics, and/or molecular characteristics).
- •Karnofsky Performance Status (KPS) >/= 70% at time of enrollment. An exception will be made for those with lower KPS at enrollment with an acute worsening that is likely to resolve in the treating physicians judgment (e.g., reversible infection,trauma, medication reaction, etc)
- •Ability to understand and the willingness to sign a written informed consent document for the Search Phase.
- •Patient willing to consider HCT
- •A preliminary search has identified:
- •An appropriate minimum 4/6 matched umbilical cord unit at intermediate resolution at HLA-A and B, and high resolution at HLA-DRB with a cell dose above 1 x 10(7) TNC/kg for a single umbilical cord blood (UCB) transplant AND
- •At least one potential 8/8 HLA-matched (HLA-A, -B, -C, and -DRB1) unrelated donor with a probability of 70% AND
- •Availability of a potential related haploidentical donor.
排除标准
- •for Search Phase:
- •Prior formal search was instituted
- •Diagnosis of acute promyelocytic leukemia (APL)
- •Known HLA matched related donor without contraindications to donate
- •Life expectancy severely limited by concomitant illness or uncontrolled infection
- •Inclusion Criteria for Transplant Phase
- •High-risk AML for which transplant is recommend based on cytogenetic, molecular and morphologic features. Patients must meet institutional standards for disease control prior to transplant.
- •For MDS. IPSS-revised criteria of high or very high at diagnosis.
- •Subject meets institutional criteria for transplant and has acceptable organ and marrow function as defined below:
- •Serum bilirubin < 2.0mg/dL unless Gilberts disease
- •Creatinine Clearance > 45 mL/min.1.73m2 as estimated by modified MDRD equation
- •Left ventricular function 40% or greater
- •DLCO corrected for hemoglobin >50%
- •KPS 70% or greater
- •An adequate graft for the defined donor type
- •Haplo-cord requires a haploidentical adult donor of 14 years of age and at least 50 kg, and a cord blood unit with at least 1.0 x 10(7) TNC/kg and a match of at least 4/6 by intermediate resolution for HLA-A and B and high resolution at DRB
- •Donor provides standard of care consent for harvest following institutional policy. Any donor samples or donor research data would be obtained on separate donor research protocol.
- •For MUD requires a 7/8 or 8/8 HLA matched unrelated donor with high resolution matching at HLA-A, -B, -C, and DRB
- •DP matching or DP permissive should be achieved when possible using T-cell epitope strategy.
- •Written informed consent for the transplant phase
- •Exclusion Criteria for Transplant Phase
- •Life expectancy severely limited by concomitant illness or uncontrolled infection
- •HIV-positive
研究组 & 干预措施
Haplo-Cord Search
Other
If subject meets the inclusion criteria and consents, will undergo a haplo-cord transplant.
干预措施: Haplo-Cord Transplant (Biological)
Matched Unrelated Donor Search (MUD)
Other
If subject meets the inclusion criteria and consents, will undergo a MUD transplant.
干预措施: Matched Unrelated Donor Transplant (Procedure)
结局指标
主要结局
Time to Transplant
时间窗: Through one year after formal search
Time to transplant will be measured from time of date of formal request to stem cell infusion date. Will also capture time from preliminary search to both formal search and transplant date.
次要结局
- Percentage of Patients Who Undergo Hematopoietic Cell Transplantation (HCT)(Through one year after formal search)
- Estimated Survival Time(From date of randomization up to 3 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Treatment for Patients With Non-Myeloid Malignancies Receiving ChemotherapyNon-Myeloid MalignanciesCancerNCT00111137Amgen718
已完成
2 期
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid NeoplasmsHigh Grade Malignant NeoplasmPreviously Treated Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaMyelodysplastic Syndrome With Excess Blasts-2Myeloid NeoplasmBlasts 10 Percent or More of Bone Marrow Nucleated CellsChronic Myelomonocytic Leukemia-2Myelodysplastic SyndromeNCT02756572University of Washington30
进行中（未招募）
2 期
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation CyclophosphamideChronic Myelogenous LeukemiaAcute LeukemiaMixed Phenotype Acute LeukemiaAcute Myelogenous LeukemiaMyelodysplastic SyndromesLymphomaChronic Lymphocytic LeukemiaAcute Lymphoblastic LeukemiaNCT04904588Center for International Blood and Marrow Transplant Research300
已完成
2 期
Gut Decontamination In Pediatric Allogeneic HematopoieticHematopoietic Stem Cell Transplantation (HSCT)Acute GVH DiseaseNCT02641236Dana-Farber Cancer Institute24
已完成
2 期
2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological MalignanciesHematopoietic and Lymphoid Cell NeoplasmNCT03712878Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University10